Cantargia AB

A Swedish listed biotechnology company

Add To Watchlist
General Information
Company Name
Cantargia AB
Founded Year
2010
Location (Offices)
Sweden +1
Founders / Decision Makers
Marcus Järås - Co-Founder, Associate Professor, Co-founder and Scientific Advisor Göran Forsberg - CEO Mats Strömqvist - Chairman Susanne Lagerlund - Senior Director, Project & Portfolio Management Peter Juul Madsen - VP CMC Lars Thorsson - VP Clinical Development Liselotte Larsson - VP Operations
Number of Employees
32
Industries
Biotechnology, Health and Wellness, Medical Devices
Funding Stage
Post Ipo Equity
Social Media

Cantargia AB - Company Profile

Cantargia is a Swedish listed biotechnology company that focuses on developing antibody-based therapies targeting IL1RAP. The company's clinical programs include nadunolimab, which is currently in phase II development for the treatment of cancer, and CAN10 in phase I development for autoimmune/inflammatory diseases. Founded in 2010, Cantargia is headquartered in Sweden. The company recently secured a significant kr250.00M Post-IPO Equity investment on 21 June 2022. This investment is indicative of the confidence that investors have in Cantargia's potential to make a meaningful impact in the field of biotechnology with its innovative antibody therapies.

Taxonomy: antibody-based therapies, clinical programs, IL1RAP, cancer treatment, autoimmune diseases, inflammatory diseases, leukemic stem cells, hematopoietic stem cells, Chronic myeloid leukemia, Acute myeloid leukemia, Acute lymphocytic leukemia, antibody-based therapy, Swedish listed company, phase II development

Funding Rounds & Investors of Cantargia AB (2)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity kr250.00M - 21 Jun 2022
Venture Round kr7.00M 2
Sunstone Capital, investor in Cantargia AB's Venture Round round
Lubio Science 		05 Jul 2013

Latest News of Cantargia AB

View All

No recent news or press coverage available for Cantargia AB.

Similar Companies to Cantargia AB

View All
argenx - Similar company to Cantargia AB
argenx United in our commitment to improve the lives of patients
Biosight Ltd. - Similar company to Cantargia AB
Biosight Ltd. Developing innovative pharmaceuticals for hematological malignancies and disorders
Cleave Therapeutics, Inc. - Similar company to Cantargia AB
Cleave Therapeutics, Inc. VCP/p97 Inhibitors for Oncology and Neurodegenerative Diseases
Actinium Pharmaceuticals, Inc. - Similar company to Cantargia AB
Actinium Pharmaceuticals, Inc. Targeted Therapies for Patients with Unmet Needs
CasInvent Pharma - Similar company to Cantargia AB
CasInvent Pharma Novel Treatment of Leukemias, Lymphomas and Solid Tumors with Highly Potent and Selective Inhibitors of CK1 Kinases
Circle Decoration Circle Decoration

Want to dive deeper into Cantargia AB? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now